

GLOBAL MARKETS FOR DRUG-DEVICE COMBINATIONS



PHM045C
January 2013

Kevin Gainer
Project Analyst

ISBN: 0-89336-243-3

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
THE IMPORTANCE OF THIS STUDY	1
INTENDED AUDIENCE	2
SCOPE AND FORMAT	2
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
SCOPE OF THE INDUSTRY	6
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET	6
<i>SUMMARY TABLE SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017 (\$ BILLIONS)</i>	7
TECHNOLOGY AND PATENT ACTIVITY	8
THE CENTRAL ROLE OF THE FDA	8
CHAPTER 3 CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY	11
OVERVIEW	11
ROLE OF THE FDA	11
<i>TABLE 1 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS</i>	12
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE	13
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE	13
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS	14
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS	15
<i>TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS</i>	15
THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS	15
<i>TABLE 3 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&D OR MANUFACTURING</i>	16
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS	18
<i>TABLE 4 TRENDS IN COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2010 (NO. OF PRODUCT SUBMISSIONS)</i>	18
<i>TABLE 5 FDA COMBINATION PRODUCT CATEGORIES IN FY2010</i>	19
CHAPTER 4 REGULATORY PROCESS AND ISSUES	21
REGULATORY FUNDING	21
FDA OFFICE OF COMBINATION PRODUCTS	21
SCOPE OF FDA ACTION	21
TREATMENT OF DEVICES	22
CLASS I DEVICES	22
CLASS II DEVICES	22
CLASS III DEVICES	22

TOPIC	PAGE NO.
CURRENT STATUS OF FDA AND NANOTECHNOLOGY INITIATIVES	23
FDA NANOTECH PRODUCT APPROVALS	24
OTHER RELEVANT HEALTH OR REGULATORY AGENCIES	24
TYPICAL REGULATORY MILESTONES IN COMBINATION PRODUCT APPROVALS	25
CLINICAL TRIALS	26
CHAPTER 5 NANOTECH COMBINATION PRODUCTS	28
OVERVIEW	28
REPRESENTATIVE COMPANIES	28
<i>TABLE 6 COMPANIES WITH SIGNIFICANT SPECIALIZATION IN NANOMEDICINE, 2012 (\$ MILLIONS)</i>	28
NATIONAL NANOTECHNOLOGY INITIATIVE	30
NANOTECH REGULATORY ENVIRONMENT	30
COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH PRODUCTS	32
NANODIAMOND DRUG DEVICES FOR CANCER TREATMENT	33
WAX NANOPARTICLES ENHANCE IMMUNE RESPONSE	34
BRAIN-PENETRATING NANOPARTICLES	34
COMBINED POLYETHYLENE GLYCOL-HYDROPHILIC CARBON CLUSTERS	35
NANO-SYRINGES	35
NANOPARTICLES PROTECT AGAINST SEXUALLY TRANSMITTED INFECTIONS	36
<i>NANOTECHNOLOGY-MAGNETISM COMBINATION IN TINY IMPLANTABLE DEVICE FOR DRUG DELIVERY</i>	36
IMPLANTS USING CONDUCTING POLYMER NANOTUBES	37
CALCIUM PHOSPHATE NANOPARTICLES FOR DRUG DELIVERY	37
NANO-SCALE DELIVERY OPTIMIZES CHEMOTHERAPY REGIMES	38
DRUG INFUSED NANOPARTICLES	39
ENCAPSULATION OF DRUG TREATMENTS IN NANOPARTICLES	40
SILICON NANOWIRES FOR DRUG DELIVERY	40
MINUTE ANTIBACTERIAL PARTICLES DESTROY DRUG-RESISTANT GERMS	41
BIODEGRADABLE CATIONIC CORE-SHELL NANOPARTICLES FOR CO-DELIVERY OF DRUGS AND GENES	42
STIMULI-SENSITIVE CORE-SHELL NANOPARTICLES FOR CANCER THERAPY	42
POLYMER-BASED NON-VIRAL GENE CARRIERS	42
MAGNETICALLY TARGETED NANOPARTICLES TO TREAT PERIPHERAL ARTERY DISEASE	43
POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY	43
<i>TABLE 7 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	44
CHAPTER 6 DRUG-ELUTING CORONARY STENTS	46
OVERVIEW	46
MECHANISM OF ACTION	46
CLINICAL TRIALS	47
DEFINITION AND SIZE OF TARGET MARKET	47
<i>TABLE 8 MARKETS FOR CORONARY STENTS, THROUGH 2017 (\$ BILLIONS)</i>	48
FDA REGULATORY ROLE WITH REGARD TO STENTS	48
FDA STENT APPROVAL HISTORY	49

TOPIC	PAGE NO.
STENT APPROVALS IN 2011-2012	51
Boston Scientific	51
Medtronic	51
Abbott	51
<i>TABLE 9 STENT APPROVAL ACTIVITY AT FDA, 2012</i>	52
PRINCIPAL DRUG ELUTED STENT PRODUCERS	52
STENT DESIGN	52
PRODUCT LINES	53
<i>TABLE 10 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE</i>	55
STENT PRODUCT INNOVATIONS AND R&D: BIOABSORBABLE STENTS	56
COMPETITIVE SITUATION	56
<i>TABLE 11 RECENT BIOABSORBABLE STENT PATENTS, 2009-2012</i>	57
R&D STATUS	57
BIODEGRADABLE COATINGS	58
MARKETS FOR STENT RELATED TECHNOLOGIES	58
LIPISCAN CORONARY IMAGING SYSTEM	58
CHAPTER 7 PHOTODYNAMIC THERAPIES	61
OVERVIEW	61
TREATMENT LIMITATIONS	61
TECHNOLOGY HISTORY	61
FIRST GENERATION DEVELOPMENTS	62
SECOND GENERATION PDT SENSITIZERS	63
PDT MARKETS FOR CANCER	63
PDT MARKETS FOR MACULAR DEGENERATION	64
PDT MARKETS FOR PSORIASIS	64
TYPES OF UVB THERAPY FOR PSORIASIS	65
PUVA PHOTOCHEMOTHERAPY	65
TARGETED PHOTOTHERAPY (EXCIMER LASER)	65
OTHER MEDICAL APPLICATIONS	66
PDT MARKET GROWTH DRIVERS	66
EXAMPLES OF PDT PRODUCTS	66
VISUDYNE (NOVARTIS)	67
LEVULAN	67
PHOTOFRIN (PORFIMER SODIUM)	67
APTOCINE	67
VISONAC	68
CEVIRA	68
LUMACAN	68
RESEARCH AND DEVELOPMENT	69
INTERVENTIONAL CARDIOLOGY	69
Cardiac Ablation	69
DERMATOLOGY	69
AUTOIMMUNE DISEASES	70
CANCER	70
Mesothelioma	70
Prostate Cancer	71

TOPIC	PAGE NO.
ANTIMICROBIAL APPLICATIONS	71
EQUIPMENT PRODUCERS	71
<i>TABLE 12 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2017 (\$ BILLIONS)</i>	71
CHAPTER 8 ANTIMICROBIALS AND OTHER MEDICAL DEVICE COATINGS	74
OVERVIEW: REGULATORY TREATMENT	74
DRIVING FORCE IN DEVELOPMENT OF ANTIMICROBIALS	74
MARKET CONTEXT AND PREVALENCE OF INFECTIONS	75
EXAMPLES OF USE	76
CLINICAL TRIALS WITH COPPER AS AN ANTIMICROBIAL	77
RELATED PRODUCTS	77
TRENDS IN FDA APPLICATIONS FOR ANTIMICROBIALS	77
<i>TABLE 13 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS THROUGH 2017 (\$ BILLIONS)</i>	78
ANTI-MICROBIAL AND OTHER MEDICAL DEVICE COATINGS	78
MARKET CATEGORIES FOR MEDICAL DEVICE COATINGS IN COMBINATION PRODUCTS	79
<i>TABLE 14 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE COATINGS, THROUGH 2017 (\$ BILLIONS)</i>	79
EXAMPLE PRODUCTS	80
<i>TABLE 15 MEDICAL DEVICE PRODUCTS INCORPORATING AN ANTIMICROBIAL FUNCTION</i>	80
CHAPTER 9 ANTIMICROBIAL CATHETERS	82
MARKET OVERVIEW	82
CLINICAL TRIALS	82
<i>TABLE 16 CURRENT FDA APPROVED CLINICAL TRIALS FOCUSED ON NEW ANTIMICROBIAL CATHETER CONCEPTS (AS OF SEPTEMBER 2012)</i>	82
APPLICATIONS	84
MARKET SIZE	84
CATHETER INNOVATIONS	85
ANTIMICROBIAL CATHETER CONCEPTS	85
SMART CATHETER CONCEPTS	86
SELENIUM NANOPARTICLES ON CATHETERS AND IMPLANTS	87
EXAMPLE PRODUCTS	87
5-FLUOROURACIL-COATED CENTRAL VENOUS CATHETER	87
ZURAGEN	88
DRUG - DEVICE COMBINATION CATHETER LOCK/FLUSH SOLUTIONS	88
R&D INITIATIVES	89
DIALYSIS CATHETERS	89
URINARY CATHETERS	90
OTHER DELIVERY TECHNIQUES	90
<i>TABLE 17 PROJECTED CATHETER MARKET BY PRODUCT TYPE, INCLUDING ANTIMICROBIAL PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	91
CHAPTER 10 DRUG-ELUTING BEADS	93
OVERVIEW	93
EXAMPLE OF THERAPY	93
COMPANY ACTIVITY	93
BEAD APPLICATIONS IN STROKE	95
BEAD APPLICATIONS IN ALLERGY AND ASTHMA ATTACKS	95

TOPIC	PAGE NO.
RECENT FDA APPROVALS	95
RECENT OVERSEAS APPROVALS FOR CLINICAL TRIALS	96
CLINICAL TRIALS	97
<i>TABLE 18 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING BEADS</i>	98
R&D AND OTHER NOVEL APPLICATIONS OF BEADS	99
USING FLUORESCENT SILICA BEADS TO DETECT MALIGNANT CERVICAL CELLS	99
ANTIBODY COATED MAGNETIC BEADS TO COMBAT INFECTION	100
FUMAGILLIN NANOPARTICLES	100
POLYETHYLENE-GLYCOL (PEG) COATED NANOPARTICLES	101
CONTROLLED DELIVERY OF TUMOR-KILLER DRUGS	102
RADIATION AND IMMUNOTHERAPY COMBINATIONS	103
POLYMERIC MICROCAPSULES	103
OHIO STATE UNIVERSITY RESEARCH	103
TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY	104
<i>TABLE 19 R&D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED BEADS, THROUGH 2017 (\$ MILLIONS)</i>	104
CHAPTER 11 BONE CEMENTS INCLUDING ANTIBIOTIC	106
GENERAL APPLICATIONS	106
ANTIBIOTIC APPLICATIONS	106
EARLY HISTORY	107
APPLICATIONS	107
MARKET SIZE	107
<i>TABLE 20 ANNUAL U.S. SALES OF BONE CEMENTS, INCLUDING COMBINATION PRODUCT ANTIBIOTIC BONE CEMENTS, THROUGH 2017 (\$ MILLIONS)</i>	108
COMPOSITION	108
EXAMPLE PRODUCTS	109
RELATED PRODUCTS: TYPES OF CERAMICS	110
BIOGRAN	110
BIO-OSS	110
BONESOURCE	110
CALCIGEN S	111
CEMENTS IN DENTAL APPLICATIONS: GLASS IONOMER CEMENTS	111
CHAPTER 12 BONE GRAFT SUBSTITUTES	113
OVERALL SIZE OF BONE GRAFT BUSINESS	113
<i>TABLE 21 PRINCIPAL COMPANIES IN THE BONE GRAFT BUSINESS</i>	114
BONE GRAFT SUBSTITUTES	114
<i>TABLE 22 PATENT ACTIVITY IN BONE GRAFT SUBSTITUTES FROM AUGUST 2010 TO AUGUST 2012</i>	115
INFUSE	116
AUGMENT	116
CARRIGEN POROUS BONE SUBSTITUTE MATERIAL	116
ALLOGRAFT TISSUE	116
OTHER OSTEOCONDUCTIVE BONE-GRAFT SUBSTITUTES	117
HYDROGELS AND NANOTUBES IN BONE GRAFTING	118
Injectable Composite Material Suitable for Use as a Bone Substitute	119
Bone Filling Complex and Method for Fabricating the Same	119

TOPIC	PAGE NO.
Composite Material	119
Device for Regeneration of Articular Cartilage and Other Tissue	120
Composition and Method for Self-Assembly and Mineralization of Peptide Amphiphiles	120
Chondroitinase ABC I Polynucleotides	120
Transdiscal Administration of Cycline Compounds	121
Composition and Method for Preparing Biocompatible Surfaces	121
Spinal Mobility Preservation Apparatus Having an Expandable Membrane	121
OSTEOBIOLOGICS AND OSTEOINDUCTIVE GROWTH FACTORS	121
BONE GRAFTS	122
<i>TABLE 23 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL</i>	123
<i>TABLE 24 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION IN THE U.S., THROUGH 2017</i>	124
<i>TABLE 25 BONE GRAFT PROCEDURE VOLUMES BY SOURCE OF GRAFT IN THE U.S. THROUGH 2017</i>	124
<i>TABLE 26 COMPARISON OF BONE GRAFT MATERIALS</i>	125
<i>TABLE 27 TYPES OF SUBSTITUTE BONE GRAFTS</i>	126
AUTOGRAFTS	126
Bioseed Grafts	127
Allografts	127
Demineralized Bone Matrix Products	129
<i>TABLE 28 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX</i>	130
Accell	130
AlphaGRAFT	130
Allomatrix	130
Grafton DBM	130
DBX	131
DynaBlast and DynaGraft-D	131
Graftech	131
Grafton	131
Opteform	132
OrthoBlast II	132
Osteofil	132
Xenografts	132
THE MARKET FOR ALLOGRAFTS	132
<i>TABLE 29 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2017 (\$ MILLIONS)</i>	132
CELL-BASED BONE GRAFT SUBSTITUTES	133
FACTOR-BASED BONE GRAFT SUBSTITUTES	134
BONE MORPHOGENIC PROTEINS	135
InductOs	135
INFUSE Bone Graft	136
OP-1 Implant	136
CERAMIC-BASED BONE GRAFT SUBSTITUTES	137
TYPES OF CERAMICS	137
Alpha-BSM	138
BioGran	138
Bio-Oss	138

TOPIC	PAGE NO.
BoneSource	138
Calcigen S	138
Collagraft Strip Bone Graft Matrix	138
Conduit TCP Granules	139
Mimix Bone Substitute Material	139
Norian SRS	139
OsteoGraf	139
Osteoset	140
OsteoStim Resorbable Bone Graft Substitute	140
PerioGlas	140
Pro Osteon Implant	140
Vitoss	140
POLYMER-BASED BONE GRAFT SUBSTITUTES	141
Cortoss	141
Healos	141
Immix Extenders and Immix CB	142
THE MARKET FOR BONE GRAFT PRODUCTS	142
<i>TABLE 30 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	143
<i>TABLE 31 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	143
REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS	143
BIOLOGIC/SYNTHETIC GRAFTS	143
CHAPTER 13 WOUND CARE PRODUCTS INCLUDING BIOLOGICAL DRESSINGS	146
WOUND CARE GENERALLY	146
<i>TABLE 32 GLOBAL COMPANIES WITH A SIGNIFICANT FOCUS IN WOUND CARE PRODUCTS</i>	146
MARKET SEGMENTS	148
COLLAGEN	148
COLLAGEN IN MEDICAL APPLICATIONS	149
<i>TABLE 33 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS</i>	149
SPECIFIC COLLAGEN PRODUCTS	150
TenoMend Collagen Tendon Wrap	150
CosmoDerm and CosmoPlast Human-Based Collagen	150
TachoSil Fibrin Sealant	151
TISSUE ENGINEERING	151
SKIN SUBSTITUTES: CELLS AND TISSUES	151
ARTIFICIAL SKIN	152
<i>TABLE 34 SKIN SUBSTITUTE PRODUCTS AND THEIR MANUFACTURERS</i>	153
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS	154
<i>TABLE 35 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2017 (\$ MILLIONS)</i>	155
ALGINATES	155
<i>TABLE 36 ALGINATE-BASED PRODUCTS AND THEIR MANUFACTURERS</i>	155
FIBRIN SEALANT PRODUCTS	156
HISTORY OF FIBRIN SEALANTS	156
FIBRIN MICROTHREADS IN TISSUE REGENERATION	157
PRODUCTS	157

TOPIC	PAGE NO.
Evicel	157
Artiss	158
ReCell	158
RELATED PRODUCTS: FIRST FDA APPROVED SPINE SEALANT	158
ENZYMATIC DEBRIDING AGENTS	159
<i>TABLE 37 ENZYMATIC DEBRIDING AGENTS AND THEIR MANUFACTURERS</i>	159
NANOSTRUCTURED TEMPERATURE-SENSITIVE MEMBRANES FOR WOUND HEALING AND CELL GRAFTING	159
<i>TABLE 38 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	160
CHAPTER 14 DRUG-DEVICE COMBINATION PRODUCTS FOR OCCULAR APPLICATIONS	162
OVERVIEW	162
FDA APPROVED OPHTHALMIC IMPLANTS	162
<i>TABLE 39 IMPLANTABLE DRUG-DEVICE OPHTHALMOLOGY COMBINATION PRODUCTS APPROVED BY FDA AS OF 2012</i>	162
VITRASERT	162
RETISERT	163
OZURDEX	163
CONTACT LENSES	163
INTRAOCULAR LENS PRODUCTS (IOL)	164
LENS MATERIALS	164
CLEAR LENS EXTRACTION AND REPLACEMENT (CLEAR) SURGERY	165
VITREOUS SUBSTITUTES	165
Polymers	166
Perfluorocarbon Liquids (PFCL)	166
Silicone Oil	166
Combination Product: PFCL and Silicone Oil	167
OCULAR DRUG DELIVERY VIA NANOSTRUCTURED DRUG-LOADED CONTACT LENSES	167
MARKET POTENTIAL	168
<i>TABLE 40 MARKETS FOR OCULAR APPLICATIONS IN DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	168
CHAPTER 15 IMPLANTABLES AS DRUG-DEVICE COMBINATIONS	170
OVERVIEW	170
NEUROMODULATION	170
MINIATURE NEUROSTIMULATORS	170
BIODEGRADABLE CIRCUITS	171
BIORESORBABLE DEVICES	172
STEROID ELUTING PACEMAKER LEADS	172
MICROELECTRONIC CONTROL OF DRUG DELIVERY	173
MARKET SIZE	173
<i>TABLE 41 IMPLANTABLE DRUG-DEVICE COMBINATIONS THROUGH 2017 (\$ MILLIONS)</i>	174
CHAPTER 16 RELATED DRUG-DEVICE COMBINATIONS OF RELEVANCE	176
OVERVIEW	176
MARKET SIZE	176

TOPIC	PAGE NO.
<i>TABLE 42 MARKETS FOR RELATED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	176
<i>INJECTABLE BIODEGRADABLE HYDROGELS FOR DRUG DELIVERY AND TISSUE ENGINEERING</i>	176
SELF-HEALING HYDROGELS	177
HYDROGELS AND MICRO ROBOTS	177
HYDROGEL SCAFFOLDING AT NANO SCALE	177
<i>IN VIVO FLEXIBLE ELECTRONICS</i>	178
HEAT ACTIVATED DRUGS	178
RADIATION/DRUG COMBINATIONS	179
ANTI-BACTERIAL RELEASING DENTAL RESTORATIVE MATERIALS	179
COMBINATION DENTAL PROPHYLAXIS PASTES AND DRUG COMPONENTS	180
BIOMIMETIC CONTROLLED-RELEASE CAPSULES FOR GUM DISEASE	180
METERED DOSE INHALERS, SPACERS AND OTHER ACCESSORIES	181
ANTIMICROBIAL SUTURES	183
ANTIMICROBIAL VASCULAR GRAFTS	183
BREATH TEST COMBINATION PRODUCTS	184
MYOCELL THERAPY BY BIOHEART, INC.	184
MICRONEEDLE DRUG AND VACCINE DELIVERY SYSTEMS	185
VACCINE DELIVERY	186
SILK-BASED MICRONEEDLE SYSTEM	186
OPHTHALMIC APPLICATIONS FOR MICRONEEDLES	187
CHAPTER 17 PATENT ANALYSIS	189
PATENT VOLUMES	189
COMPETITIVE ASPECTS	189
INTELLECTUAL PROPERTY ISSUES	189
EXAMPLES OF DRUG-DEVICE COMBINATION PATENTS: 2011 TO 2012	190
DRUG-ELUTING STENT AND METHOD OF MAKING THE SAME	190
DERMAL DELIVERY DEVICE WITH REDUCED LOSS OF ITS VOLATILE COMPONENTS	190
METHODS, DEVICES AND FORMULATIONS FOR TARGETED ENDOBRONCHIAL THERAPY	190
DRUG RELEASING COATINGS FOR MEDICAL DEVICES	191
METHOD AND APPARATUS FOR IN SITU DRUG DELIVERY DURING DISTRACTION OSTEOGENESIS	191
DRUG FORMULATIONS FOR COATING MEDICAL DEVICES	191
DRUG DEACTIVATION SYSTEM	192
LIGHT TRANSMISSION SYSTEM FOR PHOTOREACTIVE THERAPY	192
DRUG CONDENSATION AEROSOLS AND KITS	192
<i>IMPLANTABLE DRUG DEPOT FOR WEIGHT CONTROL</i>	193
DEFORMING SURFACE OF DRUG-ELUTING COATING TO ALTER DRUG RELEASE PROFILE OF A MEDICAL DEVICE	193
FLUID MANAGEMENT FLOW IMPLANTS OF IMPROVED OCCLUSION RESISTANCE	193
ANTITHROMBOTIC AND ANTI-RESTENOTIC DRUG-ELUTING STENT	194
SWITCH FOR TRANSDERMAL PATCH	194
DRUG-ELUTING BALLOON	194
BIOCOMPATIBLE COATINGS FOR STENTS	195
<i>IMPLANTABLE DRUG DELIVERY DEVICES HAVING ALTERNATING HYDROPHILIC AND AMPHIPHILIC POLYMER LAYERS</i>	195

TOPIC	PAGE NO.
DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL	195
METHOD FOR INTRAVESICAL DRUG DELIVERY	195
DELIVERY OF ANTIPSYCHOTICS THROUGH AN INHALATION ROUTE	196
NEEDLE-FREE INJECTOR DEVICE WITH AUTOLOADING CAPABILITY	196
OCULAR DRUG DELIVERY DEVICE	196
MICRONEEDLE ARRAY PATCH	197
METHODS OF ADMINISTERING TETRAZOLE-CONTAINING RAPAMYCIN ANALOGS WITH OTHER THERAPEUTIC SUBSTANCES FOR TREATMENT OF VASCULAR DISORDER	197
KINASE INHIBITORS	198
SENSORS HAVING PROTECTIVE ELUTING COATING AND METHOD THEREFOR	198
BIODEGRADABLE DRUG-POLYMER DELIVERY SYSTEM	198
DEVICE AND METHOD FOR TACKING PLAQUE TO A BLOOD VESSEL WALL	198
METHOD FOR LOADING NANOPOROUS LAYERS WITH THERAPEUTIC AGENT	199
STENTS WITH DRUG-ELUTING COATINGS	199
DRUG DELIVERY ENDOVASCULAR GRAFT	200
<i>MEDICATED COATINGS FOR IMPLANTABLE MEDICAL DEVICES INCLUDING POLYACRYLATES</i>	200
COILED WIRE FOR THE CONTROLLED RELEASE OF DRUGS TO THE EYE	200
APPARATUSES AND MEDIA FOR DRUG ELUTION AND METHODS FOR MAKING AND USING THEM	201
TRANSDERMAL PATCH	201
DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE	201
<i>PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG-ELUTING IMPLANTABLE MEDICAL DEVICE</i>	202
ONE-STEP PHOSPHORYLCHOLINE-LINKED POLYMER COATING AND DRUG LOADING OF STENT	202
SYSTEMS AND METHODS FOR DELIVERING DRUGS TO SELECTED LOCATIONS WITHIN THE BODY	202
ENDOTRACHEAL TUBE WITH FEATURE FOR DELIVERING AEROSOLIZED MEDICATION	203
METHODS AND SYSTEMS FOR SUBMUCOSAL IMPLANTATION OF A DEVICE FOR DIAGNOSIS AND TREATMENT WITH A THERAPEUTIC AGENT	203
STENTS WITH CERAMIC DRUG RESERVOIR LAYER AND METHODS OF MAKING AND USING THE SAME	203
STENT COATING FOR ELUTING MEDICATION	204
CONTROLLED RELEASE OF NITRIC OXIDE AND DRUGS FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS	204
DEVICE FOR CONTROLLED RELEASE OF CHEMICAL MOLECULES	204
<i>DRUG ELUTION FOR IMPLANTABLE INCONTINENCE DEVICES</i>	205
DRUG-ELUTING STENT AND DELIVERY SYSTEM WITH TAPERED STENT IN SHOULDER REGION	205
DRUG-ELUTING TISSUE MARKER	205
DELIVERY OF DRUG AMINES THROUGH AN INHALATION ROUTE	206
ENDOPROSTHESIS COATING	206
COGNITIVE FUNCTION WITHIN A HUMAN BRAIN	206
MEDICAL IMPLANT HAVING IMPROVED DRUG-ELUTING FEATURES	206
DELIVERY OF DRUG ESTERS THROUGH AN INHALATION ROUTE	207

TOPIC	PAGE NO.
ELECTRONICALLY-CONTROLLED DEVICE FOR RELEASE OF DRUGS, PROTEINS, AND OTHER ORGANIC OR INORGANIC CHEMICALS	207
PRELOADING WITH MACULAR PIGMENT TO IMPROVE PHOTODYNAMIC TREATMENT OF RETINAL VASCULAR DISORDERS	207
COATED AND IMPRINTED MEDICAL DEVICES AND METHODS OF MAKING THE SAME	208
METHOD FOR PHOTOTHERMAL THERAPY USING POROUS SILICON AND NEAR INFRARED RADIATION	208
EXAMPLE DRUG-DEVICE COMBINATION PATENTS: 2008 TO 2009	208
ELECTROPROCESSED COLLAGEN AND TISSUE ENGINEERING	208
BIOFUNCTIONAL, ANTIMICROBIAL COATINGS FOR MEDICAL DEVICES	209
METHOD AND DEVICE FOR DETECTING AND TREATING DEPRESSION	209
GELATIN DERIVATIVES AND HIGH-MOLECULAR MICELLE COMPRISING THE DERIVATIVES	209
METHODS AND APPARATUS FOR ACUTE OR CHRONIC DELIVERY OF SUBSTANCES OR APPARATUS TO EXTRAVASCULAR TREATMENT SITES	209
WOUND COVERING	210
NANOPARTICLES FOR PROTEIN DRUG DELIVERY	210
PROCESS FOR PROVIDING ANTIMICROBIAL SURFACES	210
GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING	211
<i>METHOD OF COATING IMPLANTABLE MEDICAL DEVICES</i>	211
ANTIMICROBIAL COATING FOR EROSIIVE ENVIRONMENTS	211
METHOD AND COMPOSITION FOR PRODUCING CATHETERS WITH ANTIBACTERIAL PROPERTY	211
<i>IMPLANTABLE MEDICAL DEVICE WITH ANTI-INFECTION AGENT</i>	212
MINIATURE DRUG DELIVERY PUMP WITH A PIEZOELECTRIC DRIVE SYSTEM	212
IONTOPHORESIS DEVICE	212
APPARATUS FOR COATING MEDICAL DEVICES	213
COATINGS FOR DRUG DELIVERY DEVICES	213
THIN-FILM DRUG DELIVERY ARTICLE AND METHOD OF USE	213
IMPLANTABLE, TISSUE CONFORMING DRUG DELIVERY DEVICE	214
<i>IMPLANTABLE DEVICE WITH RESERVOIRS FOR INCREASED DRUG LOADING</i>	214
STENT ASSEMBLY FOR THE TREATMENT OF VULNERABLE PLAQUE	214
APPLICATION OF A THERAPEUTIC SUBSTANCE TO A TISSUE LOCATION USING AN EXPANDABLE MEDICAL DEVICE	214
<i>MULTI-STABLE VALVES FOR MEDICAL APPLICATIONS AND METHODS FOR USE THEREOF</i>	215
METHOD AND APPARATUS FOR DELIVERING COMBINED ELECTRICAL AND DRUG THERAPIES	215
HEPARIN PRODRUGS AND DRUG DELIVERY STENTS FORMED THEREFROM	215
NANOPARTICLE ASSEMBLED HOLLOW SPHERES	216
METHOD OF STENT MOUNTING TO FORM A BALLOON CATHETER HAVING IMPROVED RETENTION OF A DRUG DELIVERY STENT	216
STENT HAVING AN ULTRASONIC EMITTER	216
DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE	217
<i>IMPLANTABLE DRUG DELIVERY DEVICE AND USE THEREOF</i>	217
INTRA-AORTIC RENAL DELIVERY CATHETER	217
SYSTEM AND METHOD FOR DRUG DELIVERY AND MICROFLUIDIC APPLICATIONS USING MICRONEEDLES	218

TOPIC	PAGE NO.
ENCAPSULATED INORGANIC ANTIMICROBIAL ADDITIVE FOR CONTROLLED RELEASE	218
POLYMER NANOTECHNOLOGY	218
CHAPTER 18 INDUSTRY STRUCTURE AND COMPANY PROFILES	220
OVERVIEW	220
INVESTMENT OVER LAST TEN YEARS	220
REVENUES AND PROFITABILITY	220
GLOBAL MARKET COMPETITION	221
COMPANY PROFILES	221
ABBOTT VASCULAR	221
ABL MEDICAL, LLC	222
ACRYMED, INC.	222
AFFINERGY, INC.	223
AGILE THERAPEUTICS, INC.	224
ALEXZA PHARMACEUTICALS	224
ALLERGAN, INC.	225
ALLIED MINDS/BIOTECTIX	225
ANGIOTECH PHARMACEUTICALS, INC.	225
ANTARES PHARMA, INC.	226
APTALIS PHARMA, INC.	226
ARROW INTERNATIONAL	227
AVITA MEDICAL	227
BAXTER HEALTHCARE, INC.	228
BEZWADA BIOMEDICAL LLC	228
BIND BIOSCIENCES, INC.	229
BIOCOAT, INC.	230
BIOCOMPATIBLES UK, LTD.	230
BIOHEART, INC.	231
BIOMET, INC.	232
BOSTON SCIENTIFIC CORP.	232
BRONCUS TECHNOLOGIES, INC.	233
CELSION CORPORATION	233
CODMAN & SHURTLEFF, INC.	234
COLLAGEN MATRIX, INC.	235
COMBINATION PRODUCTS COALITION	235
COOK, INC.	235
CORDIS CORPORATION	236
COVIDIEN, PLC	236
CYNOSURE, INC.	237
DELCATH SYSTEMS, INC.	237
DEPUY SYNTHES, INC. (JOHNSON & JOHNSON)	237
DISCOVERY LABORATORIES, INC.	238
DUSA PHARMACEUTICALS, INC.	239
EDWARDS LIFESCIENCES CORP.	239
ETEX CORPORATION	239
EXACTECH, INC.	240
GE HEATHCARE	240

TOPIC	PAGE NO.
INFRAREDX	241
INTEGRA LIFESCIENCES HOLDINGS CORP.	241
INTELLIJECT, INC.	242
INTERPORE CROSS INTERNATIONAL	242
ISTA PHARMACEUTICALS	243
JOHNSON & JOHNSON	243
KENSEY NASH CORPORATION	244
KIADIS PHARMA B.V.	245
LIFECCELL CORP.	245
LIGHT SCIENCES ONCOLOGY, INC.	245
LUTONIX, INC.	246
MARTECH MEDICAL PRODUCTS	246
MEDGENICS, INC.	246
MEDTRONIC, INC.	247
MERIT MEDICAL SYSTEMS, INC.	248
MICROCHIPS, INC.	248
MULTIGENE VASCULAR SYSTEMS (MGVS) LTD.	249
NOVABONE PRODUCTS, LLC	250
NOVARTIS AG	250
OMRIX BIOPHARMACEUTICALS, LTD.	251
ORBUSNEICH MEDICAL, INC.	251
ORGANOGENESIS, INC.	252
ORTHOVITA, INC.	253
PHARMACYCLICS, INC.	253
PHOTOCURE ASA	254
PHOTOBOTICS	254
PROTEUS DIGITAL HEALTH, INC.	255
PSIVIDA CORP	256
PURDUE PHARMA L.P.	256
REVA MEDICAL, INC.	257
QLT, INC.	257
SCIESENT	258
SMITH & NEPHEW, PLC	258
SORIN S.P.A.	259
STRYKER CORP.	259
SURMODICS, INC.	259
SYSTAGENIX WOUND MANAGEMENT	260
TEI BIOSCIENCES, INC.	261
VALERITAS, INC.	261
VISTA SCIENTIFIC, LLC	262
WATSON PHARMACEUTICALS, INC.	262
WRIGHT MEDICAL GROUP, INC.	263
W. L. GORE & ASSOCIATES, INC.	263
CHAPTER 19 APPENDIX 1: RECENT FDA APPROVALS OF DEVICES, INCLUDING COMBINATION PRODUCTS	265
OVERVIEW	265

TOPIC	PAGE NO.
<i>TABLE 43 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN AUGUST 2011 AND AUGUST 2012</i>	265
<i>TABLE 44 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS AUGUST 2011- AUGUST 2012</i>	266
<i>TABLE 45 MEDICAL DEVICES APPROVED BY THE FDA IN 2009</i>	266
<i>TABLE 46 MEDICAL DEVICES APPROVED BY THE FDA IN 2008</i>	267
<i>TABLE 47 MEDICAL DEVICES APPROVED BY THE FDA IN 2007</i>	268
CHAPTER 20 APPENDIX 2: GLOSSARY OF RELEVANT TERMINOLOGY	271

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ BILLIONS)	7
TABLE 1 EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS	12
TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS	15
TABLE 3 COMPANIES INVOLVED IN DRUG RELATED NANOTECHNOLOGY R&D OR MANUFACTURING	16
TABLE 4 TRENDS IN COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2010 (NO. OF PRODUCT SUBMISSIONS)	18
TABLE 5 FDA COMBINATION PRODUCT CATEGORIES IN FY2010	19
TABLE 6 COMPANIES WITH SIGNIFICANT SPECIALIZATION IN NANOMEDICINE, 2012 (\$ MILLIONS)	28
TABLE 7 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)	44
TABLE 8 MARKETS FOR CORONARY STENTS, THROUGH 2017 (\$ BILLIONS)	48
TABLE 9 STENT APPROVAL ACTIVITY AT FDA, 2012	52
TABLE 10 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE	55
TABLE 11 RECENT BIOABSORBABLE STENT PATENTS, 2009-2012	57
TABLE 12 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2017 (\$ BILLIONS)	71
TABLE 13 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS THROUGH 2017 (\$ BILLIONS)	78
TABLE 14 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE COATINGS, THROUGH 2017 (\$ BILLIONS)	79
TABLE 15 MEDICAL DEVICE PRODUCTS INCORPORATING AN ANTIMICROBIAL FUNCTION	80
TABLE 16 CURRENT FDA APPROVED CLINICAL TRIALS FOCUSED ON NEW ANTIMICROBIAL CATHETER CONCEPTS (AS OF SEPTEMBER 2012)	82
TABLE 17 PROJECTED CATHETER MARKET BY PRODUCT TYPE, INCLUDING ANTIMICROBIAL PRODUCTS, THROUGH 2017 (\$ BILLIONS)	91
TABLE 18 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING BEADS	98
TABLE 19 R&D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED BEADS, THROUGH 2017 (\$ MILLIONS)	104
TABLE 20 ANNUAL U.S. SALES OF BONE CEMENTS, INCLUDING COMBINATION PRODUCT ANTIBIOTIC BONE CEMENTS, THROUGH 2017 (\$ MILLIONS)	108
TABLE 21 PRINCIPAL COMPANIES IN THE BONE GRAFT BUSINESS	114
TABLE 22 PATENT ACTIVITY IN BONE GRAFT SUBSTITUTES FROM AUGUST 2010 TO AUGUST 2012	115
TABLE 23 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL	123
TABLE 24 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION IN THE U.S., THROUGH 2017	124
TABLE 25 BONE GRAFT PROCEDURE VOLUMES BY SOURCE OF GRAFT IN THE U.S. THROUGH 2017	124
TABLE 26 COMPARISON OF BONE GRAFT MATERIALS	125
TABLE 27 TYPES OF SUBSTITUTE BONE GRAFTS	126
TABLE 28 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX	130
TABLE 29 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2017 (\$ MILLIONS)	132
TABLE 30 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)	143
TABLE 31 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)	143
TABLE 32 GLOBAL COMPANIES WITH A SIGNIFICANT FOCUS IN WOUND CARE PRODUCTS	146
TABLE 33 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS	149

TABLE HEADING	PAGE NO.
TABLE 34 SKIN SUBSTITUTE PRODUCTS AND THEIR MANUFACTURERS	153
TABLE 35 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2017 (\$ MILLIONS)	155
TABLE 36 ALGINATE-BASED PRODUCTS AND THEIR MANUFACTURERS	155
TABLE 37 ENZYMATIC DEBRIDING AGENTS AND THEIR MANUFACTURERS	159
TABLE 38 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS, THROUGH 2017 (\$ BILLIONS)	160
TABLE 39 IMPLANTABLE DRUG-DEVICE OPHTHALMOLOGY COMBINATION PRODUCTS APPROVED BY FDA AS OF 2012	162
TABLE 40 MARKETS FOR OCULAR APPLICATIONS IN DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)	168
TABLE 41 IMPLANTABLE DRUG-DEVICE COMBINATIONS THROUGH 2017 (\$ MILLIONS)	174
TABLE 42 MARKETS FOR RELATED DRUG-DEVICE COMBINATION PRODUCTS, THROUGH 2017 (\$ MILLIONS)	176
TABLE 43 510(K) PREMARKET NOTIFICATIONS (COMBINATION PRODUCT APPROVALS) BY FDA BETWEEN AUGUST 2011 AND AUGUST 2012	265
TABLE 44 PRE-MARKET APPROVAL OF COMBINATION PRODUCTS AUGUST 2011- AUGUST 2012	266
TABLE 45 MEDICAL DEVICES APPROVED BY THE FDA IN 2009	266
TABLE 46 MEDICAL DEVICES APPROVED BY THE FDA IN 2008	267
TABLE 47 MEDICAL DEVICES APPROVED BY THE FDA IN 2007	268

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017 (\$ BILLIONS)	7